Prostate cancer
RecruitingStudy of [177Lu]Lu-PSMA-I&T Therapy for Patients with Oligometastatic Prostate Cancer Using Gozetotide and Stannous Oxide Combination
Study of [177Lu]Lu-PSMA-I&T Therapy for Patients with Oligometastatic Prostate Cancer Using Gozetotide and Stannous Oxide Combination
- Disease:Prostate cancer
- Substances:Gozetotide3,3-Diphosphono-1,2-Propanedicarboxylic Acid, Tetrasodium Salt (Dpd)+1
Austria- Participants:18–64 years · 65+ years
- Substances:Gozetotide
- Sponsor:Medical University Of Vienna









